Improving doxorubicin treatment in ovarian cancer

改善卵巢癌的阿霉素治疗

• 批准号: 10017726
• 金额: $ 52.26万
• 依托单位: TAILOR BIO LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=10017726
• 关键词: Improving; doxorubicin; treatment; ovarian; cancer

**Public description:** Genetic tests are used to guide the treatment of many cancers, but each type of cancer requires a different test. The NHS is currently combining many genetic tests into a single test covering 500 genes. This is a major step forward and offers the opportunity to extend the testing to new drug response predictions and provide more treatment options for patients.However, not all cancers will immediately benefit from a test covering 500 genes. In ovarian cancer there are currently only 2 genes which are used to help select 1 type of drug treatment - olaparib.Using novel techniques, Tailor Bio has developed a new test that identifies patients who will not respond to doxorubicin, another drug commonly used to treat ovarian cancer. After identifying these patients, clinicians can then give other types of drugs which might have greater benefit.In this project we will combine Tailor Bio's novel test with the large 500-gene tests currently being used by the NHS. As part of this project we will* Adapt software to combine the tests* Plan a clinical trial of the combined test* Investigate the cost effectiveness of the combined testSuccess in this project will allow better treatment selection for approximately 4000 people in the UK annually.

** 公开说明：** 基因检测用于指导许多癌症的治疗，但每种癌症需要不同的检测。NHS目前正在将许多基因测试合并为一个涵盖500个基因的单一测试。这是向前迈出的重要一步，并提供了将测试扩展到新药物反应预测的机会，并为患者提供更多的治疗选择。然而，并非所有癌症都能立即从涵盖500个基因的测试中受益。在卵巢癌中，目前只有2个基因用于帮助选择一种药物治疗- olaparib。使用新技术，Tailor Bio开发了一种新的测试，可以识别对阿霉素（另一种常用于治疗卵巢癌的药物）无反应的患者。在这个项目中，我们将联合收割机Tailor Bio的新测试与NHS目前使用的500个基因的大测试相结合。作为该项目的一部分，我们将 * 调整软件，以结合联合收割机的测试 * 计划的临床试验的组合测试 * 调查的成本效益的组合测试在这个项目的成功将允许更好的治疗选择约4000人在英国每年。